Impact of Vitamin D Supplementation on Recurrent Respiratory Infections in Paediatric Primary Care.
Primary Purpose
Recurrent Respiratory Tract Infections
Status
Completed
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Vitamin D3
Sponsored by
About this trial
This is an interventional prevention trial for Recurrent Respiratory Tract Infections
Eligibility Criteria
Inclusion Criteria:
- patients diagnosed the seasons before with: ≥ 6 respiratory infections per annum
- ≥ 1 respiratory infections per month involving the upper airways from September to April
- ≥ 3 respiratory infections per annum involving the lower airways
Exclusion Criteria:
- patients with findings suggestive of an immunodeficiency on history and physical examination
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
No Intervention
Arm Label
Vit D
Control
Arm Description
Vitamin D oral supplementation (400 UI/die up to 12 month or 600 UI/die beyond 1 year) from October to March
Outcomes
Primary Outcome Measures
Number of recurrent respiratory tract infections for each months of study
reduction of the number of respiratory tract infections in children diagnosed with recurrent respiratory tract infections the seasons before
Secondary Outcome Measures
Cost assessment in euros according to antibiotics, paediatric visits and vitamin D supplementation
Secondary objectives was the assessment of Vitamin D supplementation benefits on global socioeconomic burden of recurrent respiratory tract infections in a primary care setting, according to number of visits to the primary care paediatrician and use of antibiotics due to respiratory tract infections.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02617771
Brief Title
Impact of Vitamin D Supplementation on Recurrent Respiratory Infections in Paediatric Primary Care.
Official Title
Impact of Vitamin D Supplementation on Recurrent Respiratory Infections in Paediatric
Study Type
Interventional
2. Study Status
Record Verification Date
March 2019
Overall Recruitment Status
Completed
Study Start Date
October 2014 (undefined)
Primary Completion Date
March 2015 (Actual)
Study Completion Date
November 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Policlinico Hospital
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Up to date, some clinical trial have evaluated the efficacy and safety of Vitamin D supplementation in children with RRI, with no conclusive information.
Therefore, the investigators designed a prospective, single-blind, clinical trial to evaluate whether oral supplementation with vitamin D from October to April reduces the global health burden of recurrent respiratory tract infections in a primary care setting.
The primary outcome was evaluated if Vitamin D supplementation during autumn and winter can reduce the number of respiratory tract infections in children diagnosed with recurrent respiratory tract infections the seasons before.
Secondary objectives was the assessment of Vitamin D supplementation benefits on global socioeconomic burden of recurrent respiratory tract infections in a primary care setting, according to number of visits to the primary care paediatrician and use of antibiotics due to respiratory tract infections.
Detailed Description
The University study personnel randomly allocated patients to receive, from October to March, a Vitamin D oral supplementation (400 UI/die up to 12 month or 600 UI/die beyond 1 year) or not.
Randomization was performed using a free web-based service that offers random assignment; patients were randomized considering gender and age class (up to 12 months; beyond 1 years). The primary care practitioner was blinded regarding the study group allocation.
Inclusion criteria were: a) patients diagnosed the seasons before with: ≥ 6 respiratory infections per annum OR ≥ 1 respiratory infections per month involving the upper airways from September to April OR ≥ 3 respiratory infections per annum involving the lower airways. b) patients with no findings suggestive of an immunodeficiency on history and physical examination.
From the recruitment, parents recorded number and type of diagnosed respiratory tract infections, number of ambulatory visits, use of antibiotics and duration of symptoms in a structured diary.
Upper Respiratory Tract Infections (URTIs) comprehends diagnosis of acute otitis media, acute rhinosinusitis and acute pharyngotonsillitis. Lower Respiratory Tract Infections (LRTIs) comprehend diagnosis of bronchiolitis and pneumonia.
All parents had a close telephone contact to help them in the diary compilation. Adverse events related to the protocol were monitored. Missing data were recovered through the information system of the primary care practitioner.
Quantitative data were expressed as mean and standard deviation. To compare the mean between the two groups, Student's t-test for unpaired was used. The frequency of each visits to the pediatricians and use of antibiotics in the two group was calculated and expressed as a percentage. The χ² test was used to compare the percentages between the two groups. For all tests, P-values <0.05 were considered significant.
Since Italian National Health System covers all costs for pediatrician visits and antibiotics, cost assessment was made analysing the costs regarding the frequency of each parameters in treated and nontreated group. We considered as direct cost National Health System: Medical examination (20,66 euros for each examination, as provided by the Italian Ministry of Health) and use of Antibiotics (the cost was as in the list of the National Drug Authority).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Recurrent Respiratory Tract Infections
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
84 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Vit D
Arm Type
Active Comparator
Arm Description
Vitamin D oral supplementation (400 UI/die up to 12 month or 600 UI/die beyond 1 year) from October to March
Arm Title
Control
Arm Type
No Intervention
Intervention Type
Drug
Intervention Name(s)
Vitamin D3
Intervention Description
from October to March, a Vitamin D oral supplementation (400 UI/die up to 12 month or 600 UI/die beyond 1 year
Primary Outcome Measure Information:
Title
Number of recurrent respiratory tract infections for each months of study
Description
reduction of the number of respiratory tract infections in children diagnosed with recurrent respiratory tract infections the seasons before
Time Frame
From October 1, 2014, and March 31, 2015, up to 6 months
Secondary Outcome Measure Information:
Title
Cost assessment in euros according to antibiotics, paediatric visits and vitamin D supplementation
Description
Secondary objectives was the assessment of Vitamin D supplementation benefits on global socioeconomic burden of recurrent respiratory tract infections in a primary care setting, according to number of visits to the primary care paediatrician and use of antibiotics due to respiratory tract infections.
Time Frame
From October 1, 2014, and March 31, 2015, up to 6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
6 Months
Maximum Age & Unit of Time
3 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
patients diagnosed the seasons before with: ≥ 6 respiratory infections per annum
≥ 1 respiratory infections per month involving the upper airways from September to April
≥ 3 respiratory infections per annum involving the lower airways
Exclusion Criteria:
patients with findings suggestive of an immunodeficiency on history and physical examination
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Maria Elisabetta Baldassarre, MD
Organizational Affiliation
University of Bari
Official's Role
Principal Investigator
12. IPD Sharing Statement
Citations:
PubMed Identifier
25881523
Citation
de Sa Del Fiol F, Barberato-Filho S, Lopes LC, de Cassia Bergamaschi C. Vitamin D and respiratory infections. J Infect Dev Ctries. 2015 Apr 15;9(4):355-61. doi: 10.3855/jidc.5711.
Results Reference
background
PubMed Identifier
22254030
Citation
Zittermann A, Gummert JF. Nonclassical vitamin D action. Nutrients. 2010 Apr;2(4):408-25. doi: 10.3390/nu2040408. Epub 2010 Mar 25.
Results Reference
result
Learn more about this trial
Impact of Vitamin D Supplementation on Recurrent Respiratory Infections in Paediatric Primary Care.
We'll reach out to this number within 24 hrs